Trial-Results center  
Clinical trial results database in 100 Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

acute coronary syndrome - antiplatelets drug - STEMI patients

acute myocardial infarction - antiplatelets drug - all type of patients


Related trials

ERASE-MI, 2009 - elinogrel vs placebo

COMMIT, 2005 - clopidogrel vs placebo

CLARITY-TIMI 28, 2005 - clopidogrel vs placebo

APRICOT, 1993 - aspirin vs placebo

French, 1993 - flurbiprofen vs placebo

Dutch-aspirin, 1990 - aspirin vs placebo

Johannessen, 1989 - misc. vs control

ISIS-2, 1988 - aspirin vs placebo

Huddinge, 1988 - aspirin vs control

Jones, 1987 - dazoxiben vs control

ISIS-pilot, 1987 - aspirin vs placebo

GRAND, 1987 - GR3219B vs control

Dutch sulphinpyrazone, 1986 - sulfinpyrazone vs control

Knudsen-A, 1985 - ticlopidine vs control

Louvain sulphinpyrazone, 1983 - sulfinpyrazone vs placebo

Wilcox, 1980 - sulfinpyrazone vs placebo

Frankfurt, 1976 - aspirin vs control

Gent-AMI, 1968 - misc. vs control



See also:

  • All acute coronary syndrome clinical trials
  • All acute myocardial infarction clinical trials
  • All clinical trials of antiplatelets drug
  • All clinical trials of clopidogrel
  •  

    COMMIT study, 2005

    [NCT00222573] download pdf: clopidogrel | antiplatelets drug for acute myocardial infarction

    Treatments

    Studied treatment clopidogrel 75 mg daily
    Control treatment placebo
    Concomittant treatment aspirin 162 mg daily

    Patients

    Patients patients admitted to hospital within 24 h of suspected acute MI onset

    Method and design

    Randomized effectives 22961 / 22891 (studied vs. control)
    Design Parallel groups
    Blinding double-blind
    Follow-up duration until discharge or up to 4 wee
    Number of centre 1250
    Primary endpoint death, reinfarction, or stroke


    Results



    Endpoints and data reported in the trial's publication(s)

    Endpoint Events (%) Relative Risk 95% CI
    Studied treat. Control treat.
    Death, reinfarction, or stroke 2121 / 22961 (9,2%) 2310 / 22891 (10,1%) 0,92 [0,87;0,97]
    Death, any cause 1726 / 22961 (7,5%) 1845 / 22891 (8,1%) 0,93 [0,88;0,99]
    death by Arrhythmia 432 / 22961 (1,9%) 454 / 22891 (2,0%) 0,95 [0,83;1,08]
    death by Asystole 642 / 22961 (2,8%) 697 / 22891 (3,0%) 0,92 [0,83;1,02]
    death by Cardiac rupture 188 / 22961 (0,8%) 210 / 22891 (0,9%) 0,89 [0,73;1,09]
    death by Cardiogenic shock 503 / 22961 (2,2%) 562 / 22891 (2,5%) 0,89 [0,79;1,00]
    death by Reinfarction 113 / 22961 (0,5%) 101 / 22891 (0,4%) 1,12 [0,85;1,46]
    death by Stroke 72 / 22961 (0,3%) 87 / 22891 (0,4%) 0,83 [0,60;1,13]
    Other cause of death 92 / 22961 (0,4%) 103 / 22891 (0,4%) 0,89 [0,67;1,18]
    fatal Reinfarction 209 / 22961 (0,9%) 223 / 22891 (1,0%) 0,93 [0,77;1,13]
    non fatal Reinfarction 270 / 22961 (1,2%) 330 / 22891 (1,4%) 0,82 [0,70;0,96]
    All Reinfarction 479 / 22961 (2,1%) 553 / 22891 (2,4%) 0,86 [0,77;0,97]
    Not calculable (data not available)
    Ischaemic Stroke (or unknown) 164 / 22961 (0,7%) 194 / 22891 (0,8%) 0,84 [0,69;1,04]
    Haemorrhagic Stroke 55 / 22961 (0,2%) 56 / 22891 (0,2%) 0,98 [0,68;1,42]
    fatal Stroke 90 / 22961 (0,4%) 108 / 22891 (0,5%) 0,83 [0,63;1,10]
    non fatla Stroke 127 / 22961 (0,6%) 142 / 22891 (0,6%) 0,89 [0,70;1,13]
    All Stroke 217 / 22961 (0,9%) 250 / 22891 (1,1%) 0,87 [0,72;1,04]
    Cardiogenic shock 983 / 22961 (4,3%) 1043 / 22891 (4,6%) 0,94 [0,86;1,02]
    Heart failure 3033 / 22961 (13,2%) 3093 / 22891 (13,5%) 0,98 [0,93;1,02]
    Presumed cardiac rupture 209 / 22961 (0,9%) 224 / 22891 (1,0%) 0,93 [0,77;1,12]
    Ventricular fibrillation 624 / 22961 (2,7%) 655 / 22891 (2,9%) 0,95 [0,85;1,06]
    Other cardiac arrest 867 / 22961 (3,8%) 913 / 22891 (4,0%) 0,95 [0,86;1,04]
    Pulmonary embolus 32 / 22961 (0,1%) 33 / 22891 (0,1%) 0,97 [0,59;1,57]
    Fatal bleeding 73 / 22961 (0,3%) 74 / 22891 (0,3%) 0,98 [0,71;1,36]
    Cerebral fatal bleeding 39 / 22961 (0,2%) 41 / 22891 (0,2%) 0,95 [0,61;1,47]
    Non-cerebral fatal bleeding 36 / 22961 (0,2%) 37 / 22891 (0,2%) 0,97 [0,61;1,53]
    Non-fatal bleeding 61 / 22961 (0,3%) 51 / 22891 (0,2%) 1,19 [0,82;1,73]
    Cerebral Non-fatal bleeding 16 / 22961 (0,1%) 15 / 22891 (0,1%) 1,06 [0,53;2,15]
    Transfused Non-fatal bleeding 46 / 22961 (0,2%) 36 / 22891 (0,2%) 1,27 [0,82;1,97]
    Any bleeding 134 / 22961 (0,6%) 125 / 22891 (0,5%) 1,07 [0,84;1,36]

    Endpoints used by the meta-analysis and data retained for this trial

    Endpoint Studied treat.
    n/N
    Control treat.
    n/N
    Graph RR [95% CI]

    Non fatal MI

    270 / 22961
    330 / 22891
    0,82 [0,70;0,96]

    cardiovascular events

    2121 / 22961
    2310 / 22891
    0,92 [0,87;0,97]

    Non fatal stroke

    127 / 22961
    142 / 22891
    0,89 [0,70;1,13]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Ref
    Studied treat. Control treat.
    Non fatal MI 270 / 22961 (1,2%) 330 / 22891 (1,4%) 0,82 [0,70;0,96] non fatal Reinfarction  
    Non fatal stroke 127 / 22961 (0,6%) 142 / 22891 (0,6%) 0,89 [0,70;1,13] non fatla Stroke 
    cardiovascular events 2121 / 22961 (9,2%) 2310 / 22891 (10,1%) 0,92 [0,87;0,97] Death, reinfarction, or stroke 
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    Non fatal MI 1,18% 1,44% -2,7‰
    Non fatal stroke 5,53‰ 6,20‰ -0,7‰
    cardiovascular events 9,24% 10,09% -8,5‰

    Meta-analysis of all similar trials:

    antiplatelets drug in acute coronary syndrome for STEMI patients

    antiplatelets drug in acute myocardial infarction for all type of patients



    Reference(s)

    Trials register # NCT00222573
    • Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.. Lancet 2005 Nov 5;366:1607-21
      Pubmed | Hubmed | Fulltext

    (c) 2004-2014 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend

    100100